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Abstract 
Purpose: To estimate the prevalence, risk factors, prophylactic treatment and impact on mortality for venous throm-
boembolism (VTE) in patients with moderate to severe traumatic brain injury (TBI) treated in the intensive care unit.
Methods: A post hoc analysis of the erythropoietin in traumatic brain injury (EPO-TBI) trial that included twice-
weekly lower limb ultrasound screening. Venous thrombotic events were defined as ultrasound-proven proximal 
deep venous thrombosis (DVT) or clinically detected pulmonary embolism (PE). Results are reported as events, 
percentages or medians and interquartile range (IQR). Cox regression analysis was used to calculate adjusted hazard 
ratios (HR) with 95% confidence intervals (CI) for time to VTE and death.
Results: Of 603 patients, 119 (19.7%) developed VTE, mostly comprising DVT (102 patients, 16.9%) with a smaller 
number of PE events (24 patients, 4.0%). Median time to DVT diagnosis was 6 days (IQR 2–11) and to PE diagnosis 
6.5 days (IQR 2–16.5). Mechanical prophylaxis (MP) was used in 91% of patients on day 1, 97% of patients on day 3 
and 98% of patients on day 7. Pharmacological prophylaxis was given in 5% of patients on day 1, 30% of patients on 
day 3 and 57% of patients on day 7. Factors associated with time to VTE were age (HR per year 1.02, 95% CI 1.01–1.03), 
patient weight (HR per kg 1.01, 95% CI 1–1.02) and TBI severity according to the International Mission for Prognosis 
and Analysis of Clinical Trials risk of poor outcome (HR per 10% increase 1.12, 95% CI 1.01–1.25). The development of 
VTE was not associated with mortality (HR 0.92, 95% CI 0.51–1.65).
Conclusions: Despite mechanical and pharmacological prophylaxis, VTE occurs in one out of every five patients with 
TBI treated in the ICU. Higher age, greater weight and greater severity of TBI increase the risk. The development of VTE 
was not associated with excess mortality.
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Take-home message: Despite mechanical and pharmacological 
prophylaxis, venous thromboembolism occurs in one of five patients with 
traumatic brain injury treated in the intensive care unit. Older age, greater 
weight and traumatic brain injury severity increase this risk.
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Introduction
Traumatic brain injury (TBI) patients treated in the 
intensive care unit (ICU) appear at high risk for venous 
thromboembolism (VTE), such as deep venous thrombo-
sis (DVT) of the legs and pulmonary embolism (PE) [1–
3]. Moreover, the occurrence of massive PE is a known 
cause of late death in trauma patients, and the risk is 
increased in patients with DVT [4, 5]. However reported 
VTE incidence rates vary considerably in the literature 
depending on whether the diagnosis was made using 
screening protocols or only by assessing symptomatic 
patients [5, 6]. Treatment options for preventing VTEs 
include mechanical prophylaxis (MP) and pharmaco-
logical prophylaxis (PP) [7]. MP is undertaken by means 
of compressive stockings or pneumatic compression 
devices and their use may be limited in trauma patients 
with severe injuries to the lower limbs. Pharmacological 
prophylaxis is undertaken using daily injections of either 
low molecular weight heparin (LMWH) or unfraction-
ated heparin (UH) [7]. However, given the risk of aggra-
vating intracranial bleeding in TBI patients the initiation 
of pharmacological prophylaxis is commonly delayed and 
later initiation may increase the risk of VTE [2]. Despite 
the above uncertainties about true incidence, risk of PE-
related mortality and variability in the timing and extent 
of MP and PP application, there is a lack of data from 
prospectively screened large cohorts of TBI patients for 
the diagnosis of DVT with simultaneously collected data 
on the timing and use of MP and PP.
Between 2010 and 2014, we conducted the EPO-
TBI trial in 606 patients with moderate or severe TBI 
[8]. Because of the possible pro-thrombotic effects of 
erythropoietin (EPO), the study included twice-weekly 
screening leg ultrasounds (US) during ICU stay, enabling 
objective systematic assessment for DVTs [9–12]. In 
addition, the collected data included extensive evaluation 
of pre-injury risk as well as daily assessment of VTE risk 
factors and the use and type of prophylaxis. We have pre-
viously reported that the use of EPO did not increase the 
risk of VTE or other thrombotic events [8]. In the present 
study, we assessed the occurrence of VTE over time in 
the ICU and identified factors associated with the occur-
rence of VTE. We hypothesized that VTE would be more 
common in patients with a more severe TBI and that 
risk would be high in patients with delayed initiation of 
prophylaxis.
Materials and methods
The EPO-TBI trial was a multicentre, multinational, 
randomised, double-blind, parallel-group, placebo con-
trolled trial that enrolled 606 patients with non-pene-
trating moderate [best post-resuscitation, pre-intubation 
Glasgow Coma Score (GCS) 9–12] or severe (GCS 3–8) 
TBI. Patients were randomised to receive either weekly 
doses of 40,000  IU of epoetin alfa (Eprex Janssen-Cilag 
Pty Ltd, Titusville, NJ, USA) or placebo (0.9% sodium 
chloride) up to three doses or until ICU discharge. Given 
the previously reported potential pro-thrombotic effects 
of EPO, the study excluded the following patients with a 
high risk of VTE: (1) haemoglobin (Hb) level above the 
upper limit of normal at each enrolling institution, (2) 
spinal cord injury, (3) history of DVT or PE, (4) known 
chronic hypercoagulable disorder (factor Leiden V, pro-
thrombin G20210A, protein C deficiency, protein S defi-
ciency and antithrombin III deficiency, patients 3 months 
postpartum and malignancy). In addition, patients at risk 
of arterial thrombosis such as chronic renal failure with 
an arteriovenous fistula in  situ or myocardial infarction 
within the last 12 months were also excluded. The second 
and third doses of EPO were only given if the Hb did not 
exceed 120 g/L.
Patients were followed up extensively throughout 
ICU and hospital care. An electronic case report form 
included daily data on the use of blood transfusions, hae-
matology results, the use of mechanical and pharmaco-
logical VTE prophylaxis and the performance of lower 
limb US examinations while in the ICU. The occurrence 
of DVT on ultrasound and other thrombotic events were 
predefined secondary outcomes of the study.
Screening ultrasound
Bilateral compression Doppler US of the lower limbs 
was performed in the ICU at baseline and twice weekly 
until ICU discharge or for 3  weeks in total, whichever 
occurred first. In cases of clinical suspicion of a DVT, 
further US were performed as per order of the treating 
clinician. Compression ultrasounds were performed by 
either accredited US technician or a radiologist accord-
ing to local practice. Standard operating procedures for 
the performance of screening US and diagnosis of DVTs 
were used at all institutions. The US screening procedure 
focused on the deep veins of lower limbs above the knee 
i.e. (1) the trifurcation of the deep calf veins, (2) distal 
popliteal, (3) proximal popliteal, (4) distal femoral, (5) 
mid femoral and (6) common femoral. Compressibility 
of veins was tested in 1-cm increments, and non-com-
pressibility was taken to indicate thrombosis. Thrombi 
occurring in the distal part of the lower limb such as in 
the saphenous vein were documented but not considered 
a DVT. All US were performed at the bedside.
Diagnosis of pulmonary embolism
Investigations for diagnosing or ruling out PE were 
defined by the treating clinician. The study protocol 
included guidelines on PE diagnosis and management. In 
brief, PE was recommended to be diagnosed with a spiral 
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computed tomography (CT) scan of the lungs with intra-
venous contrast. The diagnosis of PE required the dem-
onstration of an intraluminal filling defect of the main, 
lobar or segmental branches of the pulmonary artery. 
Alternative diagnostic methods included ventilation-per-
fusion scanning or pulmonary angiography. In cases of 
diagnosed PE US of the lower limbs were recommended 
as well. Possible PEs diagnosed at autopsy were not sys-
tematically sought and were not included.
Use of mechanical or pharmacological prophylaxis
The use of mechanical and pharmacological DVT proph-
ylaxis was recommended and outlined in the study pro-
tocol according to the following principles: mechanical 
prophylaxis (MP) including anti-embolism compression 
stockings and/or pneumatic compression devices was 
recommended in all patients unless contraindicated. The 
use of an inferior vena cava filter could be considered in 
cases of large peripheral thrombi and the presence of an 
absolute contraindication to anticoagulation therapy. The 
recommended drug for PP was subcutaneous enoxaparin 
at 40 mg daily. Timing was recommended to be based on 
the findings of the second brain CT scan and decided in 
liaison with the neurosurgical team. Prophylaxis was rec-
ommended to be continued on hospital wards after ICU 
discharge.
Statistical analysis
A statistical analysis plan was developed a priori and 
approved by all authors. Categorical data are presented 
as numbers and percentages and compared using Chi-
square test. Numerical data are presented as medians 
and interquartile range (IQR) in parenthesis and com-
pared using the Mann–Whitney U test. Two separate 
Cox regression models were developed for time to death 
and time to occurrence of DVT with MP and PP treated 
as time-dependent variables. For the mortality model, 
patients were censored at 180-day follow-up, whilst for 
the DVT model, patients were censored at hospital dis-
charge or death. We decide a priori to include factors 
found significant in univariate analysis as well as previ-
ously reported risk factors for VTE in the model. We 
included the following known factors for VTE: age [13], 
injury severity [14], severity of TBI [15] and the pres-
ence of pelvic fracture [16]. To further account for poten-
tial heterogeneity between hospitals, location was also 
included in the multivariable model as a random effect. 
Proportionality assumptions were confirmed using Sch-
oenfeld residuals. As a further exploratory sensitivity 
analysis of the impact of pharmacological prophylaxis, 
we studied the development of VTE at various predefined 
time points (ICU days 3 and 7). For these cross-sectional 
analyses, we excluded patients that had developed a 
VTE prior to this time point. We also tested whether the 
development of VTE was associated with 6-month mor-
tality. This model included the same outcome covariates 
as specified in the main paper [17]. Associations between 
blood test values over time and the use of pharmacologic 
prophylaxis and the development of VTE were tested 
using repeated measures analysis of variance (ANOVA). 
Statistical analysis was performed with SPSS version 22.0 
(IBM Corp. Released 2013. IBM SPSS Statistics for Win-
dows, Version 22.0. Armonk, NY: IBM Corp.) and SAS 
version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
The EPO study screened a total of 3384 patients from 
May 2010 to November 2014 (Fig.  1). A total of 2778 
were not included in the study: 2645 did not meet inclu-
sion criteria and an exclusion related to risk of VTE or 
other thrombotic risk was present in 115 patients due to 
the inability to perform US, 93 due to an HB level exceed-
ing the upper level of normal, 95 due to spinal injury, 17 
due to pregnancy, 25 due to a history of DVT or PE, 17 
due to a chronic hypercoagulable disorder, 7 due to acute 
myocardial infaraction (AMI) during the last 12 months 
and 2 due to chronic renal disease and dialysis (Fig.  1). 
Thus, the study included a total of 606 patients of whom 
three withdrew consent and were excluded from analysis.
Screening ultrasounds and VTE
A median of four screening ultrasounds were performed 
per patient (IQR 2–6). Of the 603 patients, 119 (19.7%) 
developed VTE. Of these, 102 patients (16.9%) had a 
DVT of the lower extremities and 24 patients (4.0%) PE. 
Of these 119 patients, 95 (80%) had only a diagnosis of 
DVT, 17 (14%) only of PE and 7 (6%) of both DVT and 
PE. The median time to diagnosis from ICU admission 
to any form of VTE was 6 (2–12) days. The median time 
from ICU admission to diagnosis of DVT was 6  days 
(IQR 2–11); PE 6  days (IQR 2–17), and to a combined 
DVT and PE diagnosis within the same subject 7  days 
(IQR 2.5–13.5). In 14 of the 119 patients (12%), VTE was 
diagnosed on the day of randomisation and in 35 patients 
(29.4%) during the first 3 days. The development of VTE 
over time during the first 21 days in the ICU is shown in 
Fig. 2.
Unadjusted assessment of risk factors for venous 
thrombotic events
Baseline patient characteristics and prehospital treatment 
associations with the occurrence of a VTE are shown in 
Table  1. On unadjusted analysis, patients developing a 
VTE were older and had a higher body weight than those 
who did not develop a VTE. Gender was not related to 
the development of VTE in the whole cohort (Table 1), or 
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in a subset of patients under the age of 40 (377 patients) 
where 8 out of 49 (16.3%) women developed a VTE com-
pared to 44 out of 328 (13.4%) (p = 0.58). The unadjusted 
occurrence of VTE was also more common in Australia 
and New Zealand compared with other regions (Saudi 
Arabia and Europe). The occurrence of VTE was more 
common in patients with more severe general injury as 
suggested by the injury severity score, more severe TBI 
as suggested by higher IMPACT probability of poor 
outcome at 6 months and more severe critical illness as 
Fig. 1 Flow chart of included patients
Fig. 2 Proportion of patients with pharmacological prophylaxis in patients with and without VTE and cumulative incidence of VTE cases during 
the first 21 days of care in the intensive care unit. The left-hand y-axis shows the proportion of patients with pharmacological prophylaxis. The right-
hand y-axis shows the cumulative number of patients who developed a venous thromboembolism
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suggested by higher APACHE II scores (Table  1). Spe-
cific known risk factors for VTE are shown in Table 2. On 
unadjusted analysis, the presence of a pelvic fracture was 
significantly associated with the occurrence of a VTE, 
whereas family history of VTE and smoking were not. 
The transfusion of red cells or fresh frozen plasma prior 
to randomisation was more common in patients that 
developed a VTE (Table  2). In addition, initial platelet 
levels in ICU were lower in patients who developed VTE 
(Table 2).
Occurrence of VTE and use of mechanical 
and pharmacological prophylaxis
A total of 453 (75.1%) patients received some form of 
pharmaceutical prophylaxis (PP) during ICU stay and 
overall, when assessed in isolation, such treatment was 
not different in patients who developed VTE compared 
to those who did not (71 vs. 76%, p = 0.30). In the unad-
justed analysis, delay in initiation of such prophylaxis 
was longer in those who developed a VTE (median 6, 
IQR 3–10) compared to those who did not (median 4, 
IQR 3–6) (p < 0.001) (Supplementary Table 4). By day 3, 
181 (30%) patients had received PP, and this proportion 
was lower in those who developed a VTE compared to 
those who did not (20 vs. 32%, p = 0.009) (Supplemen-
tary Table 4). By day 7, 343 (57%) patients had received 
PP, and this proportion was lower in patients who devel-
oped a VTE compared to those who did not (43 vs. 60%, 
p = 0.001) (Supplementary Table 4). The use of PP over 
time in those patients who developed VTE and those that 
Table 1 Demographic data including mechanism of injury and injury severity of included patients
Characteristic All patients (n = 603) VTE (n = 119) No VTE (n = 484) p value
Mean age (years) 30.5 (22.6–47.9) 43.2 (24.5–52) 28.5 (22.1–44.8) <0.0001
Female gender 101 (17%) 24 (20%) 77 (16%) 0.27
Weight (kg) 75 (65–86.5) 80 (72–92.5) 75 (65–85) <0.001
Geographical region
  Australia or New Zealand 315 (52.2%) 78 (24.8%) 237 (75.2%) <0.001
  Saudi Arabia or Europe 288 (47.8%) 41 (14.2%) 247 (85.8%)
Mechanism of injury
  Motor vehicle accident 237 (39.3%) 44 (37.0%) 193 (39.9%) 0.70
  Motorcycle 70 (11.6%) 13 (10.9%) 57 (11.8%)
  Bicycle 26 (4.3%) 2 (1.7%) 24 (5.0%)
  Pedestrian 58 (9.6%) 12 (10.1%) 46 (9.5%)
  Fall/jump 138 (22.9%) 31 (26.1%) 107 (22.1%)
  Hit by object 51 (8.5%) 12 (10.1%) 39 (8.1%)
  Other 23 (3.8%) 5 (4.2%) 18 (3.7%)
TBI severity
  Moderate TBI (GCS 9–12) 149 (24.7%) 25 (21.0%) 124 (25.6%) 0.3
  Severe TBI (GCS 3–8) 454 (75.3%) 94 (79.0%) 360 (74.4%) 0.3
  Median GCS 7 (4–9) 6 (3–8) 7 (4–9) 0.06
Prehospital care
  Systolic blood pressure less than 90 mmHg 190 (31.5%) 47 (39.5%) 143 (29.5%) 0.036
  Oxygen saturation less than 90% 115 (19.1%) 38 (31.9%) 77 (15.9%) <0.0001
Severity of TBI, illness and trauma
  IMPACT-TBI probability of poor outcome 45.8% (27.0–66.0) 52.7% (39.1–71.8) 39.1% (27.0–59.5) <0.001
  APACHE II score 19 (15–25) 21 (16–16) 19 (15–24) 0.009
Abbreviated injury score
  Head 4 (3–5) 4 (4–5) 4 (3–5) 0.44
  Face 0 (0–2) 0 (0–2) 0 (0–2) 0.35
  Chest 2 (0–3) 2 (0–3) 2 (0–3) 0.37
  Abdomen/pelvis 0 (0–0) 0 (0–2) 0 (0–0) 0.009
  Extremity 0 (0–2) 0 (0–2) 0 (0–2) 0.45
  External 0 (0–1) 1 (0–1) 1 (0–1) 0.006
Injury severity score 26 (19–33) 29 (22–34) 25 (18–33) 0.004
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did not is shown in Fig. 2. There were unadjusted regional 
differences in the initiation of PP with median delay to 
initiation in Australia and New Zealand of 5  days (IQR 
3–9) compared to 4 days (IQR 2–5) in Europe and 4 days 
(IQR 3–6) in Saudi Arabia (p < 0.001). There was no dif-
ference in mean haemoglobin levels over time based on 
whether the patient received PP or not (95 vs. 95  g/l, 
p =  0.86). In addition, there was no difference in mean 
activated thromboplastin time (APTT) values over time 
and the use of PP (32 vs. 31.9 s p = 0.478). There were no 
significant differences in the use of mechanical prophy-
laxis at day 1, 3 or 7 in patients who developed a VTE and 
those who did not (Supplementary Table 4).
Blood transfusion and blood values and VTE
In patients who developed a VTE after day 3 the median 
volume of red cells transfused prior to day 3 was 520 ml 
(IQR 471–797  ml) compared to 560  ml (IQR 300–
815 ml) in those who did not develop a VTE (p = 0.30). 
In patients who developed a VTE after day 7 the median 
volume of red cells transfused prior to day 7 was 523 ml 
(IQR 470–849) and 600 ml (IQR 500–1000 ml) in those 
who did not (p = 0.53). Blood transfusion prior to day 3 
or 7 did not increase the risk of developing a VTE at a 
later stage (Supplementary Tables 6, 7). The mean labo-
ratory values of haemoglobin, international normalized 
ratio (INR), platelet count, and APTT and the adminis-
tration of red blood cells, platelets, fresh frozen plasma 
and clotting products are shown in the electric supple-
mentary material in Supplementary Figs. 3–6. There was 
no correlation between levels of haemoglobin (p = 0.67), 
platelets (p = 0.56), INR (p = 0.74) and VTE. There was 
no difference between VTE patents and those without 
with regards to transfusion of red cells (44% compared 
to 37%, p  =  0.21), platelets (7.6% compared to 8.3%, 
p =  0.80), fresh frozen plasma (10% compared to 8.3%, 
p =  0.53) or other clotting products (2.5% compared to 
1.7%, p = 0.53) as shown in Supplementary Figs. 3–6.
Multivariate modelling for development of VTE
At ICU admission, independent predictors for the develop-
ment of VTE were age (HR 1.02, 95% CI 1–1.03, p = 0.01), 
weight (HR 1.01, 95% CI 1–1.02, p =  0.011) and severity 
of TBI according to the IMPACT risk of poor outcome 
(HR 1.12, 95% CI 1.01–1.25, p  =  0.030) (Supplementary 
Table  5). Factors associated with time to development 
Table 2 Differences in patients with and without a venous thrombotic event
Characteristic All patients (n = 603) VTE (n = 119) No VTE (n = 484) p value
Risk factors
  Family history of VTE 7 (1.2%) 3 (2.5%) 4 (0.8%) 0.12
  Pelvic fracture 74 (12.3%) 21 (17.6%) 53 (11.0%) 0.046
  Femoral fracture 37 (6.1%) 9 (7.6%) 28 (5.8%) 0.47
  Oestrogen 12 (2%) 0 (0%) 12 (2.5%) 0.08
  Significant immobility in past 3 months 0 (0%) 0 (0%) 0 (0%) NA
  Smoker 179 (29.7%) 32 (26.9%) 147 (30.4%) 0.46
  None 347 (57.5%) 65 (54.6%) 282 (58.3%) 0.47
Blood transfusions prior to randomisation
  Red cells (%) 154 (25.5%) 41 (34.5%) 113 (23.3%) 0.013
  Platelets (%) 57 (9.5%) 14 (11.8%) 43 (8.9%) 0.34
  Fresh frozen plasma (%) 91 (15.1%) 29 (24.4%) 62 (12.8%) 0.002
  Other clotting product (%) 45 (7.5%) 12 (10.1%) 33 (6.8%) 0.23
  None (%) 422 (70.0%) 74 (62.2%) 348 (71.9%) 0.038
Previous medication
  Unfractionated heparin 0% 0% 0% NA
  Low molecular weight heparin 1 (0.2%) 0 (0%) 1 (0.2%) 0.62
  Warfarin 2 (0.3%) 1 (0.8%) 1 (0.2%) 0.28
  Aspirin 10 (1.7%) 2 (1.7%) 8 (1.7%) 0.98
  Other 1 (0.2%) 0 (0%) 1 (0.2%) 0.62
Initial haematological parameters
  Haemoglobin 121 (104–134) 120 (101–136) 121.5 (104–133.5) 0.53
  INR 1.2 (1.1–1.2) 1.1 (1.1–1.2) 1.2 (1.1–1.25) 0.49
  APTT 29.8 (27–32.6) 29.2 (27–33) 29.8 (27–32.4) 0.72
  Platelets 194 (156–239) 185 (148–223) 198 (163–241) 0.012
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of VTE in the ICU (excluding those patients with VTE 
present at the baseline screening ultrasound) with Cox 
regression are shown in Table 3. The use and time to phar-
macological prophylaxis was not independently associated 
with the development of VTE (Table 3). In a further explor-
atory analysis, the absence of PP on day 3 (HR 2.3, 95% CI 
0.98–5.47, p = 0.06) or day 7 (HR 1.72, 95% CI 0.86–3.44, 
p  =  0.13) was not independently associated with VTE 
development thereafter (Supplementary Tables 6, 7).
Occurrence of VTE and outcome
Patients who developed VTE had significantly longer 
ICU and hospital stays, at 17 (IQR 11–22) and 33 (IQR 
20–56) days compared to 12 (6–19) and 23 (13–40) 
days, respectively (p  <  0.001 for both). Median time on 
mechanical ventilation was longer in patients who devel-
oped VTE compared to those who did not, 11 days (IQR 
6–17) compared to 8 (IQR 4–14), p  <  0.001. There was 
no difference in ICU (89.1 vs. 90.5%), hospital (88.2 vs. 
88.4%) or 6-month survival (86.6 vs. 87.2%) but good 
neurological outcome was less common in those who 
developed a VTE (45.4 vs. 57.9%, p  =  0.01). Survival 
curves for patients alive at 7 days and at ICU discharge 
who had developed a VTE prior to that time point are 
shown in the Supplementary Fig.  7. In a multivariate 
model including age, presence of hypotension or hypoxia, 
presence of an intracranial mass lesion, pupils of equal 
size and reacting to light, study treatment EPO/placebo, 
the development of VTE was not associated with mortal-
ity (HR 0.81, 95% CI 0.45–1.45) (Supplementary Table 8).
Factors associated with occurrence of pulmonary 
embolism
Patient who developed a PE were older than those who 
did not (49.5 IQR 24.5–58.5 vs. 30.3 IQR 22.5–46.9, 
p = 0.01) (Supplementary Table 9). Pulmonary embolism 
was diagnosed more commonly in Australia and New 
Zealand than in Europe and Saudi Arabia (5.7 vs. 2.1%, 
p = 0.02). There was no difference in TBI severity, critical 
illness or injury severity (Supplementary Table 9). There 
was no difference in either risk factors, blood transfu-
sions, admission haematological parameters or previous 
medication use in patients who developed PE and those 
who did not (Supplementary Table 10).
Discussion
Key findings
In this post hoc analysis of a multicentre international 
randomised controlled trial with prospective screen-
ing for DVT by means of compression leg ultrasound, 
we found that VTE occurs in approximately one out of 
every five patients with TBI, with almost a third occur-
ring in the first 3  days. Moreover, we found that injury 
severity, age and weight are the three major independent 
risk factors for VTE, while delay in the use of mechani-
cal prophylaxis was not found to be an independent pre-
dictor of VTE. Pharmacologic prophylaxis is commonly 
delayed and its impact on the development of VTE is 
unclear. Finally, VTE was more common in patients with 
prolonged ICU length of stay but was not independently 
associated with increased mortality.
Relationship with previous studies
The occurrence of VTE including proximal DVT was 
common in the present study and much higher than 
reported in a recent review of all studies on TBI patients, 
which found a reported VTE rate of 2.8% in over 4000 
cases [2]. Interestingly our rate of proximal DVT is simi-
lar to rates found in the 1990s by Geerts et al. in a land-
mark study of 349 patients with major trauma [6], where 
Table 3 Cox regression model for factors associated with VTE
Outcome Univariate HR (95% CI) p value Multivariate OR (95% CI) p value
Age (years) 1.02 (1.01–1.03) 0.001 1.02 (1–1.03) 0.010
Weight (kg) 1.02 (1.01–1.03) 0.002 1.01 (1–1.02) 0.011
Region Australia and New Zealand 2.12 (1.27–3.53) 0.004 2.09 (0.99–4.4) 0.053
Region Europe 0.77 (0.39–1.53) 0.460 0.66 (0.28–1.57) 0.35
No family history of VTE 0.72 (0.1–5.14) 0.740 1.09 (0.15–8.01) 0.93
No pelvic fracture 0.64 (0.39–1.06) 0.081 0.64 (0.37–1.1) 0.11
Early transfusion of red cells or FFP 0.78 (0.52–1.17) 0.230 1.15 (0.73–1.84) 0.54
Injury severity score 1.02 (1–1.04) 0.056 1 (0.98-1.02) 0.83
IMPACT risk of poor outcome (in 10%) 1.15 (1.05–1.25) 0.002 1.12 (1.01–1.25) 0.03
APACHE II score 1.02 (0.99–1.05) 0.133 0.97 (0.93–1) 0.08
Intervention (placebo vs. EPO) 1.17 (0.79–1.72) 0.438 1.45 (0.97–2.16) 0.07
Use of pharmacological prophylaxis (days) 0.65 (0.4–1.04) 0.069 0.75 (0.46–1.24) 0.27
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venography was used for screening and a proximal DVT 
rate of 18% was found. Our results are also comparable 
to those of the recent study by Robertson and colleagues 
on TBI patients [11]. This suggests that there has been no 
major change in VTE rates in trauma patients over the 
last 20–30 years.
The rate of both DVTs and PE is about four times 
greater in TBI patients than in general medical and sur-
gical ICU patients [18]. The PROTECT study included 
over 4000 critically ill patients but excluded patients 
with major trauma. It compared the use of dalteparin or 
unfractionated heparin for the prevention of VTE [18]. 
It included an identical ultrasound screening protocol as 
in our study and found a 5.5% rate of DVT and a 1.8% 
rate of PE. The reasons for the higher incidence of VTE 
in TBI patients are likely multifactorial and may include 
fractures of the pelvis and lower extremity and, perhaps, 
delays in initiation of PP. Indeed, studies have shown the 
use of inappropriate pharmacologic prophylaxis in up to 
70% patients with major trauma [19].
The optimal timing for the initiation of PP in TBI 
patients has, however, not been defined [7]. In the cur-
rent study, we found a clear association between later ini-
tiation of PP and the development of VTE in univariate 
analysis. However, this association was lost with multi-
variate modelling. This suggests that PP delays may sim-
ply be more common in patients with severe TBI who 
are independently prone to VTE. The point estimate of 
the hazard ratios does, however, suggest a potential but 
limited protective benefit. A lack of statistical power may 
have contributed to this finding.
Our findings that age and weight are important risk 
factors for the development of VTE are consistent with 
previous literature [20]. The age-related effect has been 
attributed to increases in various coagulation factors 
[21], increased tendency to platelet aggregation [22], 
impaired fibrinolysis [23] and pathophysiologic changes 
in the vasculature [24]. Previous studies have also linked 
obesity with the development of VTE [19]. This may be 
related to venous stasis [25] and a pro-thrombotic state 
[26]. It is also possible that the doses of PP used in the 
current study in heavier patients were too low. Indeed 
studies have suggested that weight-adjusted dosing of PP 
is important in order to achieve therapeutic levels of anti-
factor Xa [27]. Dosing of PP guided by anti-Xa measure-
ments has been shown to reduce the incidence of DVT 
without increasing bleeding rates [28].
In the recent study by Robertson and colleagues on the 
use of a haemoglobin threshold of 100 g/l in TBI patients 
for blood transfusion resulted in a higher prevalence of 
VTE [11]. In the current study we did not find any clear 
association with either haemoglobin or coagulation 
parameters and transfusion of red blood cells or other 
blood products, and the development of VTE. Regarding 
PE there were much less profound differences in patients 
developing PE and those who did not. This makes selec-
tive prophylactic strategies aiming at specifically reducing 
the risk of PE in high-risk patients difficult to implement. 
One such intervention with uncertain indications is the 
prophylactic placement of vena cava filters [29].
Implications of study findings
Our findings imply that in a population of patients with 
moderate to severe TBI one out of every five patients 
may develop either DVT or PE. Moreover, our findings 
imply that greater injury severity, older age and over-
weight should trigger consideration for particularly active 
surveillance and earlier and more aggressive protec-
tive measures whenever possible. Future studies should 
explore whether screening measures and earlier initia-
tion of pharmacological prophylaxis are safe and effective 
in critically ill TBI patients. Finally, the observation that 
close to one-third of VTE events occur in the first 3 days 
implies that such surveillance should start as soon as pos-
sible after ICU admission.
Study strengths and limitations
This study has several strengths. It is the largest study to 
date of TBI patients to include a robust screening proto-
col for DVTs with regular lower limb ultrasonography. 
Its double-blind randomised controlled design allowed 
a clear understanding of the effect of EPO on the risk 
of DVT and VTE and provided a high level of internal 
validity. Its multicentre and multinational features pro-
vide a high degree of external validity. The collection of 
detailed daily data on VTE prophylaxis provides the first 
detailed insight into the current preventive manage-
ment of VTE in TBI patients. However, our study also 
carries some limitations. Because of the possible pro-
thrombotic effects of EPO, certain subgroups of patients 
were excluded, creating a selection bias. Thus, the overall 
true VTE incidence in unselected TBI patients might be 
even higher then reported in our study. It is noteworthy 
that some of the patients were excluded because of the 
inability to perform lower limb US. This may represent 
a patient group with both a high risk of DVT and a need 
for other screening strategies than US. In addition, our 
study case report form did not include patient height and 
thus we were unable to calculate body mass index which 
might have shown an even stronger relationship with 
VTE risk.
We also did not collect data on time of mobilisation and 
active infection or inflammation, which could contribute 
to the development of VTE. In addition, given the mul-
ticentre design of the study several different approaches 
to pharmacological prophylaxis were used, which may 
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have influenced the occurrence of VTE [30]. Moreover, 
although we linked delayed PP with increased risk of 
VTE, we cannot confirm if such increased risk reflects 
the delayed PP per se or whether both delayed PP and 
increased risk reflect injury severity not fully captured by 
the illness severity scores used in our study.
Conclusions
In this large multicentre trial one in five patients with 
traumatic brain injury developed VTE despite rapid 
and near complete use of mechanical prophylaxis. This 
observed rate of VTE is four times higher than observed 
in other critically ill patients, with one-third of events 
developing within the first 3 days. Moreover, injury sever-
ity, older age and increasing weight are key independent 
risk factors for VTE.
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